Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2016-04-01
2022-07-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study arm
Experimental arm
Serum samples are collected:
* at each neoadjuvant chemotherapy cycle
* before surgery
* at each adjuvant chemotherapy cycle
* at each injection of bevacizumab as maintenance therapy
* stop at the progression or after 24 months post chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental arm
Serum samples are collected:
* at each neoadjuvant chemotherapy cycle
* before surgery
* at each adjuvant chemotherapy cycle
* at each injection of bevacizumab as maintenance therapy
* stop at the progression or after 24 months post chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient scheduled to undergo neoadjuvant chemotherapy based on platinum followed by surgery and adjuvant chemotherapy
* Age ≥ 18 years .
* Performance status ECOG \> or = 2
* Adequate haemoglobin rate ≥ 10 g/dL
* Ability to provide written informed consent
* Patient's legal capacity to consent to study participation
Exclusion Criteria
* Patient with visceral metastases
* Contraindication for blood test
* Contraindication for surgery
* Contraindication for bevacizumab treatment
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de Cancérologie de Lorraine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Céline Gavoille, MD
Role: PRINCIPAL_INVESTIGATOR
Institut de Cancérologie de Lorraine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GAVOILLE Céline
Vandœuvre-lès-Nancy, Institut de Cancérologie de Lorraine, France
SAVOYE Aude-Marie
Reims, Institut Jean Godinot, France
BENGRINE-LEVEVRE Leïla
Dijon, Centre Georges François Leclerc, France
DEMARCHI Martin
Strasbourg, Centre Paul Strauss, France
LONGO Raphaelle
Metz, CHU Metz Thionville, France
KURTZ Jean-Emmanuel
Strasbourg, Hôpital Civil, France
KALBACHER Elsa
Besançon, Hôpital Jean Minjoz, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-A01511-46
Identifier Type: -
Identifier Source: org_study_id